Marta Velasco
About Marta Velasco
Marta Velasco is an Inmuno-Oncology Sales Representative at Bristol-Myers Squibb with over 15 years of experience in the pharmaceutical and oncology sectors.
Current Position at Bristol-Myers Squibb
Marta Velasco currently holds the position of Immuno-Oncology Sales Representative at Bristol-Myers Squibb. She has been with the company for over seven years, focusing on developing and managing sales strategies in the field of immuno-oncology. Her role includes collaborating with healthcare professionals to support the use of immuno-oncology therapeutics.
Previous Experience at Boehringer Ingelheim
Before joining Bristol-Myers Squibb, Marta Velasco worked at Boehringer Ingelheim. From 2013 to 2016, she served as a Product Specialist in Oncology, based in Ingelheim, Rheinland-Pfalz, Germany. Prior to that role, she was a Medical Sales Delegate at the same company from 2006 to 2008, focusing on building relationships with medical professionals to promote the company's pharmaceutical products.
Tenure at Novartis Oncology
Marta Velasco has substantial experience with Novartis Oncology. She worked as a Medical Scientific Liaison from 2012 to 2013, where she was involved in providing scientific and technical support for oncology products. Before that, from 2009 to 2011, she was a Sales Representative in the oncology division, focusing on driving sales and market penetration for oncology products.
Early Career in Pharmaceutical Sales
Marta Velasco began her career in the pharmaceutical industry in 2003 with Grupo Alter, where she worked as a Medical Sales Delegate for two years. From 2006 to 2008, she continued in a similar role at Boehringer Ingelheim. These roles laid the foundation for her expertise in sales and relationship management within the pharmaceutical sector.
Educational Background
Marta Velasco completed her Master's degree over the course of one year from 2001 to 2002. This educational achievement provided her with foundational knowledge that has been integral to her career in the pharmaceutical and oncology sectors.